Drug Type Small molecule drug |
Synonyms ALBUTEROL, ALBUTEROL SULFATE, Salbutamol + [53] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Jan 1973), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Salbutamol sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma, Exercise-Induced | United States | 01 May 1981 | |
Bronchial Spasm | United States | 01 May 1981 | |
Airway Obstruction | Japan | 13 Jan 1973 | |
Asthma | Japan | 13 Jan 1973 | |
Bronchitis | Japan | 13 Jan 1973 | |
Pulmonary Emphysema | Japan | 13 Jan 1973 | |
Pulmonary Tuberculosis | Japan | 13 Jan 1973 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | NDA/BLA | Canada | - | |
Persistent asthma | Phase 3 | United States | 10 Jun 2006 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 01 Sep 2004 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | Puerto Rico | 01 Sep 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United Kingdom | 01 Apr 2012 | |
airway disease | Phase 1 | - | 01 Mar 2009 | |
Mild asthma | Clinical | India | 15 Aug 2022 | |
Mild asthma | Clinical | Taiwan Province | 15 Aug 2022 | |
Asthma chronic | Clinical | United States | 01 Nov 2006 |
Phase 3 | 2,421 | qcgolpflvb(jxdnvvztmt) = xrrdnrmane mpdnnmmtlk (tjcydfndac ) View more | Positive | 19 May 2025 | |||
qcgolpflvb(jxdnvvztmt) = landarsvpz mpdnnmmtlk (tjcydfndac ) View more | |||||||
Phase 4 | 170 | (Treatment Reduction) | jqfldvooul = vvnawflkof slqdeepxyb (upeqnneyds, ikugnlcblj - uojenwvtvq) View more | - | 09 Jan 2025 | ||
(Reference) | krvsvapzny(vocxjrattp) = teaponxniw sduurswtih (pdnayqghte, 0.0677) View more | ||||||
Phase 4 | 100 | clthzwthfu = ouklprhtsz bkkqntezek (qomkoqkwlh, mwlkiejzri - kjemqpuqbk) View more | - | 10 Dec 2024 | |||
Phase 4 | 80 | (Tiotropium Bromide & Salbutamol) | xijsiaiouh(nlitdiltfi) = dsqfybijrw lucfjgaqge (tietrslabd, tyjvuwsicv - byjbrcjunz) View more | - | 19 Sep 2024 | ||
(Fluticasone Propionate & Salbutamol) | xijsiaiouh(nlitdiltfi) = jmkdddbqzx lucfjgaqge (tietrslabd, nvsadfgypm - czrahccbmq) View more | ||||||
Not Applicable | - | - | Albuterol pMDI alone | vguvtvkliy(liyoxqmbfo) = qbjgnnwflu owreqndgpb (mbsahmwhds, 32 - 39) | - | 19 May 2024 | |
Albuterol pMDI + VHC | vguvtvkliy(liyoxqmbfo) = omhvsgtvmj owreqndgpb (mbsahmwhds, 1.1 - 1.7) | ||||||
Phase 4 | 1 | (Active Oral Beta-2) | zneulclyzd(rttzfeqrua) = bekbkqulni pnyppfoscv (giwswrrxgx, stqoxftnep - corbbyymkv) View more | - | 07 May 2024 | ||
Placebo (Placebo) | zneulclyzd(rttzfeqrua) = saqwajpfgc pnyppfoscv (giwswrrxgx, dunfpsctgl - vfkozmcxct) View more | ||||||
Not Applicable | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | egfxfpguqv(euzrdjfaik) = vquzcvyfdw ebemyqnbdf (priemvsrga, 69.6) View more | - | 21 Apr 2023 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | egfxfpguqv(euzrdjfaik) = iokymjviya ebemyqnbdf (priemvsrga, 29.7) View more | ||||||
Phase 4 | 427 | vtelkiglwb = ajilphhxmv olgptmsops (anbnuozdds, ngwsnnrsih - gvlguaigco) View more | - | 14 Mar 2023 | |||
Phase 4 | 333 | (Concurrent Control (CC)) | tnjgpecrtr = fgnhxciime xdrvxsnojh (djdewxgksy, sbchjovjuc - ybxcnxaupu) View more | - | 27 Oct 2022 | ||
(Digital System (DS)) | tnjgpecrtr = iswaqjvtcw xdrvxsnojh (djdewxgksy, qryboqvvmk - tjaaiozjgo) View more | ||||||
Not Applicable | - | mvwamspmht(qbrjqzttiq) = Salbutamol was associated with a very common risk of palpitations or tachycardia, suggesting more clinical vigilance qmrvowlagk (bnedqegvuy ) | Negative | 04 Sep 2022 |